Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Amgen's Oncology Strategy: Building A Pipeline Of Novel Paradigm-Changing Drugs

Executive Summary

Amgen oncology development VP Greg Friberg talked to Scrip about the company's rapidly growing oncology portfolio. "This is our renaissance," he said.

Advertisement

Related Content

Q&A: SVP Elliott Levy On Amgen R&D's 'Singular Focus On Innovation'
AML Paradigm Shift: Doctors Welcome Many New Approvals And Approaches
ASH Preview: BCMA-Targeting CAR-Ts And Bispecifics Hog The Spotlight
FDA Grants Blincyto Accelerated Approval Based On MRD Response Endpoint
Amgen gains early US win for BiTE antibody Blincyto
Amgen buying Onyx for $10.4 billion to be bigger player in cancer therapies
Amgen to swallow $1.16B Micromet in one BiTE, like a cytotoxic T cell on a tumour
Pfizer granted accelerated OK for Xalkori in NSCLC ahead of schedule

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC125375

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel